Strontium for Health & Longevity
Evidence Review created on 09/25/2026 using AI4L + evidence-mcp / Grok 4
Also known as: Strontium ranelate, Strontium citrate, Strontium chloride, Strontium carbonate, Strontium gluconate, Strontium aspartate, Strontium L-Lactate, Protelos, Protos, Osseor, Protaxos, Bivalos
Motivation
Strontium is a mineral chemically close to calcium, and stable salts of it can enter bone in calcium’s place. The prescription salt strontium ranelate was developed to slow bone breakdown while also supporting bone formation. Supplement salts, especially strontium citrate, are sold with a similar aim. For adults focused on health and longevity, the draw is fracture prevention: a broken hip or spine in later life often costs mobility and raises the chance of an earlier death.
Europe authorized strontium ranelate for severe osteoporosis. It was never approved in the United States. Large studies in older women reported fewer spine fractures and higher bone-density readings. Those readings are partly inflated, because strontium blocks X-rays more than the calcium it replaces. Heart-attack and blood-clot signals led to tight limits on who could receive the drug. The manufacturer later stopped selling it in Europe and asked that the authorization be withdrawn. Citrate supplements stayed on sale with much less human testing.
This review examines fracture and bone-density findings, joint-structure results, heart and clot risks, and how dosing and monitoring differ between the withdrawn prescription salt and the salts sold as supplements. The focus is the evidence, not a course of action.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
High-level overviews that discuss strontium itself, not only bone health in general.
- Osteoporosis and Bone Health - Maureen Williams et al.
Life Extension’s bone protocol summarizes ranelate trial results, the later heart and clot restrictions, and the thin human evidence for strontium citrate combinations.
- Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis. - Deeks & Dhillon, 2010
Narrative review of strontium ranelate, developed and studied under Servier sponsorship, covering fracture results, bone-density changes, and tolerability including nausea, diarrhea, and clot reports.
- Cardiac concerns associated with strontium ranelate. - Reginster, 2014
A safety review of the heart-attack signal seen with ranelate in trials, the absence of a matching rise in cardiovascular deaths inside those trials, and the exclusions that followed.
Fewer than five items are listed. A 4 September 2021 members-only FoundMyFitness Q&A has a segment titled Strontium, but that recording is not publicly retrievable, so it is not listed. Searches of Peter Attia, Andrew Huberman, Chris Kresser, and Lifespan.io did not return a piece that discusses strontium by name. Life Extension’s protocol is the priority-source exception. The list was not padded with general bone articles.
Grokipedia
Grokipedia’s strontium page covers the element plus medical uses, health effects, and therapeutic controversies. A separate page covers the withdrawn ranelate salt in more detail.
Examine
Examine’s strontium page summarizes supplement forms, the separation from calcium, the lack of fracture trials for non-ranelate salts, and cardiovascular cautions drawn from the prescription salt.
ConsumerLab
Serious Cardiovascular Risks Associated with Strontium, Health Canada Warns
ConsumerLab reports Health Canada’s 2015 warning that strontium supplements be avoided by people with heart, circulation, or clot risk, based on ranelate trial signals at 680 mg elemental daily.
Systematic Reviews
Systematic reviews and meta-analyses of strontium ranelate on fractures, knee osteoarthritis, and heart-attack comparisons, with FRAX (a 10-year fracture-risk score) and SIDIAP (a Catalan primary-care record system) named in two titles.
- Strontium ranelate for preventing and treating postmenopausal osteoporosis. - O’Donnell et al., 2006
Four trials, mostly in postmenopausal women, show fewer vertebral and nonvertebral fractures at 2 g daily, plus more diarrhea and a possible vascular signal.
- A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®). - Kanis et al., 2011
Pooled Servier phase 3 data showed about a 31% lower rate of clinical fractures, with a similar relative effect across FRAX (a 10-year fracture-risk score).
- Strontium ranelate as a possible disease-modifying osteoarthritis drug: a systematic review. - Rodrigues et al., 2018
Review of clinical and animal studies reporting slower knee osteoarthritis progression and some symptom change with strontium ranelate.
Meta-analysis of two primary-care databases, including SIDIAP (a Catalan record system), comparing heart-attack rates on ranelate with alendronate.
A systematic review devoted to venous clots was not among the most relevant results. Clot findings are taken up in the risks section from the trial record and a later multi-country analysis. The heart-attack meta-analysis above is the risk-side review in this list. The fracture reviews are the benefit side. No systematic review of strontium citrate was found.
Mechanism of Action
Strontium ranelate dissociates into two strontium ions and ranelic acid. The ion does the biological work. It mimics calcium at CaSR (calcium-sensing receptor, a surface sensor that sets the pace of bone turnover) but stimulates that sensor more weakly than calcium. In bone-cell experiments the ion increases osteoblasts (cells that build bone), raises collagen production, and increases OPG (osteoprotegerin, a decoy that lowers RANKL (receptor activator of nuclear factor-κB ligand, the signal that forms osteoclasts, the cells that break bone down) signaling). RANKL is thereby dampened, so fewer osteoclasts form. Developers described the net effect as a tilt toward formation. That account is not uniform: in rats after ovary removal, one experiment did not find increased bone formation (Fuchs et al.).
In humans, about 27% of a 2 g oral dose reaches the blood, and calcium taken at the same time cuts absorption sharply (Reginster, 2002). The ion is not a substrate of liver drug-metabolizing enzymes. It is cleared by the kidney and the gut. A single-dose study followed serum strontium for 240 hours, which fits slow plasma clearance, on the order of days rather than hours (Zhang et al.). Once built into bone mineral it stays for years, which is what later density scans detect (Boivin et al.). Selectivity is low: it is a calcium stand-in, and the skeleton holds nearly all of the retained dose. Citrate and other supplement salts are assumed to supply the same ion. They lack this pharmacokinetic package.
Historical Context & Evolution
Stable strontium was identified in 1790 near Strontian, Scotland. It was not an osteoporosis treatment. Radioactive strontium-89, used for cancer bone pain, is a different product from the stable salts in supplements and in ranelate.
Servier developed strontium ranelate and settled on 2 g daily, about 680 mg elemental strontium. Two large placebo-controlled trials paid for by Servier reported fewer fractures in postmenopausal women with osteoporosis. Europe authorized it in 2004 as Protelos and related names. The United States did not. Bisphosphonates (drugs that slow bone breakdown) were already cheap and reimbursed, while ranelate was branded and citrate is paid out of pocket. That cost gap may bias what payers fund. It does not explain the later withdrawal.
Pooled safety data then showed more myocardial infarction (MI, heart attack) and more venous thromboembolism (VTE, a vein clot that can reach the lungs) than placebo, without a clear rise in cardiovascular deaths inside the trials. Regulators limited use to severe osteoporosis when other treatments did not fit, and excluded cardiovascular disease and uncontrolled hypertension. Servier stopped European marketing in 2017. The authorization was withdrawn, at the company’s request, on 14 April 2020 (European Medicines Agency).
Citrate stayed on sale near that same elemental dose. Its studies are small, uncontrolled, or mixed with other nutrients. The fracture results and the clot and heart signals belong to the ranelate program. The later change was the safety reading and the loss of the licensed product, not a trial that reversed the fracture findings.
Expected Benefits
High 🟩 🟩 🟩
Fewer Vertebral Fractures
In postmenopausal women with osteoporosis, 2 g of oral strontium ranelate daily led to fewer new vertebral fractures than placebo. The main Servier-sponsored trial found a relative risk (RR, event rate on treatment divided by the rate on placebo) of 0.59 over three years. A Cochrane review pooled a similar reduction (RR 0.63) (O’Donnell et al.). The 95% confidence interval (CI, the range compatible with the data) is given below. This fracture result is in women who already had osteoporosis, and strontium citrate has not been tested this way.
Magnitude: RR 0.59 (95% CI 0.48 to 0.73) for new vertebral fractures over three years with 2 g daily strontium ranelate versus placebo (Meunier et al.).
Fewer Nonvertebral Fractures
A second Servier-sponsored trial, in 5,091 postmenopausal women, found fewer fractures outside the spine with the same 2 g dose. The relative reduction was modest for all nonvertebral fractures. Hip fracture fell more only in a high-risk slice: age at least 74 years and a very low femoral-neck T-score (density scored against a young-adult average). The Cochrane pool agreed in direction (O’Donnell et al.). The evidence is ranelate, not citrate, and the hip figure is a subgroup.
Magnitude: About a 16% relative reduction in all nonvertebral fractures over three years, and a 36% relative reduction in hip fracture among women aged at least 74 years with femoral-neck T-score at or below −3 (Reginster et al.).
Higher Bone Mineral Density
Dual-energy X-ray absorptiometry (DXA, a two-energy X-ray bone-density scan) readings at the spine and hip rise on ranelate. Part of the rise is physical: strontium blocks X-rays more than calcium, about ten percent extra per one molar percent replaced. After adjustment, a treatment-related lumbar increase remains. Density is a validated surrogate, but on strontium it is not pure calcium bone. Men and non-ranelate salts lack a fracture-counted density trial of the salt alone (Kaufman et al.; Maria et al.).
Magnitude: At three years, lumbar-spine bone mineral density rose 12.7% from baseline on ranelate, a 14.4% difference versus placebo (P<0.001, the probability a difference this large arose by chance). After adjustment for strontium in bone, the from-baseline rise was 6.8% and the treatment-related increase was 8.1% (Meunier et al.; Blake & Fogelman).
Medium 🟩 🟩
Slower Loss of Knee Joint Space
One Servier-sponsored trial tested 1 g and 2 g of strontium ranelate daily for three years in knee osteoarthritis. Both doses slowed loss of medial joint space by a fraction of a millimeter. Symptom scores moved more clearly at 2 g. The trial has not been repeated as an independent confirmation program, and it used ranelate. The finding is about joint structure and symptoms, not about lifespan.
Magnitude: Over three years, medial joint-space loss was 0.14 mm less than placebo at 1 g daily and 0.10 mm less at 2 g daily (Reginster et al.).
Low 🟩
Speculative 🟨
Longer Remaining Lifespan
Fewer fractures might preserve later years of life. A model in women over 80 turned fracture reductions into more remaining years, yet no trial showed fewer deaths. Basis is extrapolation only.
Benefit-Modifying Factors
-
Prior fracture and low density: Fracture trials enrolled postmenopausal women with osteoporosis, often with a prior vertebral fracture. The same relative effect is not established in people with normal density.
-
Vitamin D and calcium status: Both arms of the large trials received calcium and vitamin D. The reported fracture effect assumes that background, with calcium timed away from the strontium dose.
-
Sex: Vertebral and nonvertebral fracture results are in postmenopausal women. In men, a two-year trial showed a lumbar density gain similar in direction, without a fracture count (Kaufman et al.).
-
Age: Participants were mostly in their seventies. The hip signal was confined to women aged at least 74 years with very low femoral-neck density, so the oldest high-risk group is where that endpoint appeared.
-
Kidney filtration: Strontium is excreted by the kidney. Advanced loss of filtration was a reason the 2 g ranelate dose was not used, so the trial benefit does not extend to that group.
-
Genetic variants: Variants in CaSR are a research topic. No inherited variant is used to choose a strontium dose or to predict who gains fewer fractures.
Potential Risks & Side Effects
High 🟥 🟥 🟥
Venous Thromboembolism
Clots in the legs or lungs were more common with strontium ranelate than placebo in the trial program. A later five-country analysis, with Servier-affiliated authors, still found more VTE with current than past use, an excess of about one quarter to one third. People with a prior clot, and people immobilized for a long time, were later kept off the drug. Citrate has no clot trial of its own.
Magnitude: Odds ratio (OR, the odds of the event on one exposure divided by the odds on another) 1.30 (95% CI 1.04 to 1.62) for VTE with current versus past strontium ranelate (Ali et al.).
Diarrhea and Nausea
Gastrointestinal upset is the common tolerability issue in the ranelate trials. The Cochrane review found more diarrhea at 2 g daily, and a pharmacology review lists nausea among frequent longer-term complaints (Deeks & Dhillon). These effects often start early and were not a clear driver of serious adverse events or of stopping overall. The dose is taken apart from food, which can make nausea more noticeable.
Magnitude: RR 1.38 (95% CI 1.02 to 1.87) for diarrhea with 2 g daily strontium ranelate versus placebo in trials of at least one year, about 6.5% versus 4.7% (O’Donnell et al.).
Medium 🟥 🟥
No risk is graded Medium: clot and diarrhea findings come from more than one trial, and the heart findings conflict across trial and observational designs.
Low 🟥
Myocardial Infarction ⚠️ Conflicted
Pooled trials found more myocardial infarction on ranelate than placebo. Those counts were not checked by a review committee, and cardiovascular deaths were not higher. A Danish comparison did not reproduce that excess (Svanström et al.). No citrate trial measured heart attacks. The finding is not stable across study designs.
Magnitude: In pooled trials, MI occurred in 1.7% on ranelate versus 1.1% on placebo (OR 1.6, 95% CI 1.07 to 2.38) (Reginster).
Cardiovascular Death ⚠️ Conflicted
Placebo-controlled trials did not show higher cardiovascular mortality with ranelate. One comparison with bisphosphonates did, with Servier coauthors and no placebo arm. A death hazard is not established in the trials and appears in only one observational contrast.
Magnitude: OR 1.35 (95% CI 1.02 to 1.80) for cardiovascular death with current ranelate versus current oral bisphosphonate use (Ali et al.).
Severe Drug Reaction With Rash
Severe rashes with ranelate include DRESS (drug reaction with eosinophilia and systemic symptoms, a rash with high eosinophil counts and organ inflammation) and can include liver injury. They can start within weeks and can be fatal, so suspected cases are not rechallenged. Trials did not report a controlled rate.
Magnitude: Not quantified in available studies. Published evidence is case reports without a controlled incidence (di Meo et al.).
Memory Disturbance
Longer-term ranelate treatment has been linked to memory loss. A pharmacology review lists it among the most common complaints in extended use, and a Cochrane review noted a slight rise in nervous-system effects at 2 g daily. This was not a primary trial endpoint.
Magnitude: In additional safety data from the Cochrane review, memory loss was 2.4% with 2 g daily ranelate versus 1.9% with placebo over three to four years (O’Donnell et al.; Deeks & Dhillon).
Headache
Headache was slightly more common with 2 g of ranelate daily than placebo in additional trial safety data. It was not a primary endpoint, and no significant pooled risk ratio is given. The gap is a tolerability note, not a severe event.
Magnitude: Headache was 3.9% with ranelate versus 2.9% with placebo in that additional data over three to four years (O’Donnell et al.).
Seizures
The same Cochrane safety summary notes a small rise in seizures with 2 g of ranelate daily. Counts were low, this was not a primary endpoint, and no citrate trial has measured seizures.
Magnitude: Seizures were 0.3% with ranelate versus 0.1% with placebo in that additional pooled data (O’Donnell et al.).
Disturbance in Consciousness
Additional safety data list disturbance in consciousness (a change in alertness) as slightly more common on ranelate than placebo. It was not a primary endpoint. The absolute difference is small.
Magnitude: Disturbance in consciousness was 2.5% with ranelate versus 2.0% with placebo in that additional data (O’Donnell et al.).
Dermatitis and Eczema
Product labeling lists dermatitis (inflamed skin) and eczema as common in the first years of ranelate use, at rates close to placebo. They are separate from the rare severe rash with organ inflammation. Citrate has no matching skin trial.
Magnitude: Pooled early trial tables give dermatitis 2.1% versus 1.6% and eczema 1.5% versus 1.2% (Blake & Fogelman, 2006). The tolerability pattern is also reviewed by Deeks & Dhillon.
Speculative 🟨
Risk-Modifying Factors
-
Prior clot or immobilization: A past VTE, or current bed rest, was treated as a reason not to use ranelate, because the clot signal sits on top of that baseline risk.
-
Cardiovascular history: Established ischemic heart disease, peripheral artery disease, cerebrovascular disease, and uncontrolled hypertension were later exclusions, which is where the MI signal is most concerning.
-
Kidney filtration: Strontium leaves through the kidney. The ranelate dose was not used below a creatinine clearance of 30 mL/min, where accumulation is expected.
-
Sex: The safety database is mostly postmenopausal women. Men have a smaller density trial and far less information on clots and heart attack.
-
Age: Trial participants were largely over 70, the same ages at which baseline clot and heart risk are already higher. The oldest adults carry both the fracture context and that background risk.
-
Early weeks of exposure: DRESS, when it occurs, clusters in the first weeks to months. Diarrhea also tends to appear early rather than after years.
Key Interactions & Contraindications
-
Calcium (calcium carbonate, calcium citrate): Caution. Taken together, calcium sharply cuts strontium absorption, so less of the dose is retained. Separate by at least two hours.
-
Dairy foods and calcium-fortified products: Caution. The same absorption drop occurs with a calcium-rich meal. The ranelate dose was taken at bedtime, away from food.
-
Antacids (aluminum hydroxide, magnesium hydroxide): Caution. These bind divalent ions and can lower strontium absorption. Separate by at least two hours.
-
Tetracyclines (antibiotics; doxycycline, tetracycline): Caution. Strontium may bind them in the gut, as calcium does, and lower antibiotic absorption. This is theoretical. Separate by at least two hours.
-
Quinolone antibiotics (ciprofloxacin, levofloxacin): Caution. The same binding concern applies and has not been tested directly for strontium. Separate by at least two hours so the antibiotic dose is not lost.
-
Oral bisphosphonates (alendronate, risedronate): Caution. Both change bone turnover. Fracture trials of ranelate were against placebo, not added on top of a bisphosphonate, so any combined effect is unmeasured, and the ranelate clot risk would remain.
-
Vitamin D: Monitor. Trials gave vitamin D with calcium in both arms, apart from the strontium dose. It supports mineral handling. It does not replace fracture evidence and does not remove clot risk.
Populations who should avoid Strontium:
- Current or past ischemic heart disease, peripheral arterial disease, cerebrovascular disease, or uncontrolled hypertension.
- Prior venous thromboembolism, or current immobilization such as prolonged bed rest.
- Creatinine clearance below 30 mL/min.
- A prior DRESS-type reaction or hypersensitivity to strontium ranelate.
- Pregnancy and lactation, where human outcome data are lacking.
- Children and adolescents, in whom excess strontium with poor calcium intake has been tied to impaired bone growth.
Risk Mitigation Strategies
-
Screen before heart or clot risk: Ranelate was later limited to people without prior venous thromboembolism, ischemic heart disease, or uncontrolled hypertension, the setting of those signals.
-
Stop for clot or heart symptoms: New one-sided leg swelling, sudden breathlessness, or chest pressure is the point at which ranelate was stopped, because clots and heart attack were the serious signals.
-
Permanent stop after a severe rash: Suspected DRESS means an immediate stop and no re-exposure. The rash can begin within the first weeks.
-
Watch early diarrhea and nausea: These complaints are more common at 2 g daily in the first weeks than later, and they were not why the trials stopped treatment overall.
-
Record new memory complaints: Memory loss is described as common in longer ranelate use, without a controlled rate, so a new memory change is noted rather than ignored.
Therapeutic Protocol
-
Trial regimen, ranelate: Servier’s phase 3 trials (Meunier; Reginster) used 2 g of strontium ranelate orally once daily, about 680 mg elemental, at bedtime and away from food. The product is withdrawn.
-
Supplement regimen, citrate: Life Extension’s bone protocol, and similar catalogs, use about 680 mg elemental strontium from citrate once daily, at least two hours from calcium. Fracture efficacy is unproven.
-
Other bone drugs as alternatives: Bisphosphonates, denosumab (an antibody that slows bone breakdown), and teriparatide (a parathyroid-hormone drug that builds bone) are separate interventions used when cardiovascular exclusions removed ranelate. They are named here, not ranked as a default.
-
Time of day: Bedtime dosing, at least two hours after the last calcium-containing meal, is the pattern in the ranelate trials and on most citrate labels.
-
Half-life and schedule: Plasma strontium is still measurable a day and more after a dose, and bone retention lasts years, so the studied pattern is once daily, not several times a day.
-
Single dose, not split: The fracture trials used one daily dose. Splitting is not what those trials tested, and it does not solve the calcium-separation problem.
-
No gene-based dose: CaSR and other variants are not used to pick a strontium dose. No pharmacogenetic algorithm is in clinical use for this ion.
-
Sex: Fracture dosing evidence is in postmenopausal women. The male trial used the same 2 g ranelate dose and measured density, not fractures.
-
Age: The studied adults were mostly over 70. The hip subgroup was 74 years and older. The same dose was not retitrated by decade.
-
Baseline density: The fracture protocol was studied in osteoporosis, not in people with a normal density scan. A normal baseline is outside that evidence.
-
Conditions that change the regimen: Prior cardiovascular disease, prior VTE, and creatinine clearance below 30 mL/min removed people from ranelate use. Those facts change whether the trial dose was ever considered, not the milligrams inside it.
Discontinuation & Cycling
-
Duration: Ranelate was studied as continuous treatment over three to eight years, not as a short course. Citrate supplements are likewise often continued without a defined stop date.
-
Withdrawal effects: No acute withdrawal syndrome is described. Density readings can fall after the salt is stopped, in part because bone strontium, which inflates the scan, declines.
-
Taper: Product information did not require a taper. Stopping was abrupt in ordinary use. Suspected DRESS means immediate cessation, not a taper.
-
Cycling: No trial shows that time off and time on preserves the fracture effect. The evidence that exists is for continuous daily use of ranelate.
Sourcing and Quality
-
Two different products: Strontium ranelate was a prescription granule (Protelos and related names) and is withdrawn in the European Union. It was never approved in the United States. Citrate, chloride, and carbonate salts are sold as supplements.
-
Elemental amount: Labels that matter state elemental strontium, not only the weight of the whole salt. The trial dose corresponded to about 680 mg elemental.
-
Third-party testing: For supplements, a USP (United States Pharmacopeia) or NSF (independent testing group) certificate is the quality mark. ConsumerLab’s note on strontium is a safety warning, not a brand ranking.
-
Catalog brands: Life Extension and similar sellers offer strontium citrate capsules with an elemental dose on the label. The brand name does not replace a test of contents.
-
Not the radioactive isotope: Strontium-89 injections for cancer pain, and environmental strontium-90, are different substances. They are not substitutes for a stable salt.
Practical Considerations
-
Time to effect: In the spine-fracture trial, a vertebral fracture reduction was already reported in the first year. Density readings keep changing over several years, including the artifact from strontium in bone.
-
Common pitfalls: Taking the dose with calcium or dairy, treating a raw DXA rise as pure new bone, and assuming citrate has the same fracture data as ranelate are the recurring errors.
-
Regulatory status: Ranelate’s European authorization was withdrawn on 14 April 2020 at Servier’s request. Citrate is sold in the United States as a dietary supplement, not as an approved treatment for osteoporosis.
-
Access and cost: Ranelate is effectively unavailable. Citrate supplements are inexpensive and widely sold, so cost is not the barrier. The evidence gap is.
Interaction with Foundational Habits
-
Sleep: Direction is none established for sleep architecture. The practical point is indirect: bedtime dosing on an empty stomach can cause nausea that wakes someone, so gastrointestinal tolerance is the sleep-related issue, not a stimulant effect.
-
Nutrition: Direction is blunting if calcium or dairy is ingested with the dose, because the two minerals compete for absorption, and potentiating for the bone context if vitamin D is replete and calcium is taken at another time of day. Trials fed calcium and vitamin D to both groups, separated from ranelate.
-
Exercise: Direction is independent and potentially additive. Resistance and impact loading signal bone through mechanical strain, which is a different path from the CaSR effect of the ion. No trial shows that strontium blunts muscle gain. The fracture trials did not replace exercise with the drug.
-
Stress management: Direction is none established on cortisol. Any link is indirect, through pain and lost mobility after a fracture, not through a measured change in the stress response. No timing rule relative to stress practices comes from the trials.
Monitoring Protocol & Defining Success
Before a strontium salt is started, a DXA of the spine and hip, serum calcium, creatinine clearance or estimated glomerular filtration rate (eGFR, a blood estimate of kidney filtration), and 25-hydroxyvitamin D set the baseline later results are judged against. Blood pressure and a history of heart disease, stroke, or clots belong in that same pass, because those facts decided whether ranelate was permitted.
Ongoing checks follow the trial cadence: DXA at about 12 months and then every 12–24 months, with kidney filtration and calcium at baseline, at about 3 months, and then yearly. Earlier review fits a new rash with fever, one-sided leg swelling, or chest pain. If turnover markers are used, they are repeated yearly. Density change is read against the person’s own baseline, with the strontium X-ray artifact kept in view.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| DXA, lumbar spine and hip | No established target on strontium; track percent change from the person’s own baseline | Shows whether the reading is moving, including artifact | Strontium inflates the value; compare with the pretreatment scan. Conventional T-score categories assume calcium-only bone |
| 25-hydroxyvitamin D | 40–60 ng/mL | Background for the mineral effect seen in trials | Conventional sufficiency is often cited near 30 ng/mL. Trials repleted vitamin D in both arms |
| Serum calcium | 9.0–10.0 mg/dL, mid-normal | Detects calcium imbalance while strontium is used | Conventional range is about 8.6–10.2 mg/dL. Fasting morning sample |
| Creatinine clearance or eGFR | At or above 90 mL/min | Strontium is renally cleared | Ranelate labeling used 30 mL/min as the floor. Conventional eGFR “normal” is often at or above 90, with 60–89 called mildly reduced |
| CTX | No fixed target; a fall from the person’s baseline is the signal used in trials | Resorption context | C-terminal telopeptide, a blood marker of bone breakdown. Morning fasting sample. Not a fracture test |
| P1NP | No fixed target; direction versus the person’s baseline | Formation context | Procollagen type I N-propeptide, a blood marker of bone formation. Often paired with CTX. Optional |
Qualitative markers:
- New or worsening mid-back pain, loss of height, or a new fracture on imaging.
- Calf swelling, sudden shortness of breath, or chest pressure, as clot and heart signals.
- Loose stools, nausea, or a widespread rash with fever in the first months.
- Walking speed, ability to rise from a chair, and usual physical activity, as function rather than a scan number.
Emerging Research
-
No recruiting fracture trial: A ClinicalTrials.gov search on 25 September 2026, intervention term strontium, found no recruiting study of oral strontium for osteoporosis, fractures, or longevity. Completed work includes a small strontium L-Lactate pharmacokinetic study (NCT03761979) and a finished melatonin-micronutrient osteopenia trial (NCT01870115).
-
Citrate and fractures: Whether about 680 mg elemental strontium from citrate changes fracture rates is untested. A positive trial would strengthen supplement claims; a null trial would weaken them. Current human citrate data are a small combination trial and an uncontrolled series (Maria et al.; Genuis & Bouchard).
-
Ion versus carrier: Studies that separate the strontium ion from ranelic acid on heart attack and clot outcomes could strengthen or weaken the case for citrate. Existing cardiovascular syntheses are about ranelate (Reginster; Ali et al.).
Conclusion
Strontium, as the prescription salt ranelate, has a fracture record the supplement salts lack. In older women with osteoporosis it was tied to fewer spine fractures and a smaller drop in other fractures, with a hip finding mainly in those already at high risk. Density readings rose, yet much of that rise is strontium in bone blocking X-rays, not only new calcium mineral. One large trial also found slightly slower loss of knee joint space. Servier sponsored those studies and later had staff on a multi-country safety analysis, so the record is not independent of the manufacturer.
Clots were more common. Heart attacks were more common in the pooled trials, but routine-care studies did not consistently show that excess, and cardiovascular deaths were not higher against placebo. A rare rash with organ inflammation is known from case reports. Europe withdrew the license after marketing stopped. Citrate is still sold without its own fracture trial, so a heart or clot concern for citrate is an analogy.
For an adult looking at health across later life, this is evidence about fractures and mobility when bones are already fragile, not about slowing aging in general. It sits beside a clot risk and an unsettled heart-attack picture. The studied prescription product is no longer sold, and a density scan on any strontium salt has to be read with the X-ray artifact in mind.